Evidence map›Paper›PMID 25156823›Full record

ArticleCellular and molecular neurobiology2014

Imipramine ameliorates pain-related negative emotion via induction of brain-derived neurotrophic factor.

Seiko Yasuda, Mitsuhiro Yoshida, Hirotaka Yamagata, Yasutake Iwanaga, Hiromi Suenaga, Kozo Ishikawa, Masako Nakano, Satoshi Okuyama, Yoshiko Furukawa, Shoei Furukawa and 1 more

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular neurobiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity.The international journal of neuropsychopharmacology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Seiko YasudaDivision of Neurosciences, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.
Mitsuhiro Yoshida
Hirotaka Yamagata
Yasutake Iwanaga
Hiromi Suenaga
Kozo Ishikawa
Masako Nakano
Satoshi Okuyama
Yoshiko Furukawa
Shoei Furukawa
Toshizo Ishikawa
Yamaguchi University · JPMatsuyama University · JPSapporo Medical University · JPGifu Pharmaceutical University · JPKyushu Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depression-like behavior is often complicated by chronic pain. Antidepressants including imipramine (IMI) are widely used to treat chronic pain, but the mechanisms are not fully understood. Brain-derived neurotrophic factor (BDNF) is a neuromodulator that reduces depression by regulating synaptic transmission. We aimed to characterize the antidepressant effects of IMI without analgesia based on BDNF (trkB)-mediated signaling and gene expression in chronic pain. A chronic constriction injury (CCI) model was constructed in Sprague-Dawley (SD) rats. IMI (5 mg/kg, i.p.) was administered from day 10 after CCI. The pain response was assessed using the paw withdrawal latency (PWL) and depression was judged from the immobility time in a forced swim test. Anti-BDNF antibody, K252a, or 5,7-dihydroxytryptamine (5,7-DHT) were used to examine the antidepressant effects of imipramine. Changes in pERK1/2 (immunohistochemistry), 5-HT and BDNF (ELISA), and BDNF mRNA (RT-PCR) were measured in the anterior cingulate cortex (ACC), rostral ventromedial medulla (RVM), and spinal cord. After CCI, rats showed decreased PWL and increased immobility time. A low dose of IMI reduced the immobility time without having analgesic effects. This antidepressant effect was reversed by anti-BDNF antibody, K252a, and 5,7-DHT. IMI reduced excessive activation of pERK1/2 associated with decreased pCREB and BDNF mRNA, and these changes were reversed by 5,7-DHT. These results show that IMI reduces pain-related negative emotion without influencing pain and that this effect is diminished by denervation of 5-HT neurons and by anti-BDNF treatment. IMI also normalizes derangement of ERK/CREB coupling, which leads to induction of BDNF. This suggests a possible interaction between 5-HT and BDNF.

Indexed as

Emotions5,7-DihydroxytryptamineAnimalsAntidepressive AgentsBrain-Derived Neurotrophic FactorChronic PainConstriction, PathologicCyclic AMP Response Element-Binding ProteinDisease Models, AnimalExtracellular Signal-Regulated MAP KinasesGene Expression RegulationGyrus CinguliImipramineMalePhosphorylationRats, Sprague-Dawley5,7-DihydroxytryptamineAntidepressive AgentsBrain-Derived Neurotrophic FactorCyclic AMP Response Element-Binding ProteinExtracellular Signal-Regulated MAP KinasesImipramineRNA, MessengerSerotonin

Identifiers

PMID25156823
PMCPMC11488886
OpenAlexW1987131637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.